Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Oxid Med Cell Longev ; 2022: 1630918, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-1714452

RESUMEN

BACKGROUND: The impairment of microcirculation is associated with the unfavorable outcome for extracorporeal membrane oxygenation (ECMO) patients. Studies revealed that pulsatile modification improves hemodynamics and attenuates inflammation during ECMO support. However, whether flow pattern impacts microcirculation and endothelial integrity is rarely documented. The objective of this work was to explore how pulsatility affects microcirculation during ECMO. METHODS: Canine animal models with cardiac arrest were supported by ECMO, with the i-Cor system used to generate nonpulsatile or pulsatile flow. The sublingual microcirculation parameters were examined using the CytoCam microscope system. The expression of hsa_circ_0007367, a circular RNA, was measured during ECMO support. In vitro validation was performed in pulmonary vascular endothelial cells (PMVECs) exposed to pulsatile or nonpulsatile flow, and the expressions of hsa_circ_0007367, endothelial tight junction markers, endothelial adhesive molecules, endothelial nitric oxide synthases (eNOS), and NF-κB signaling activity were analyzed. RESULTS: The pulsatile modification of ECMO enhanced microcirculatory perfusion, attenuated pulmonary inflammation, and stabilized endothelial integrity in animal models; meanwhile, the expression of hsa_circ_0007367 was significantly upregulated both in animals and PMVECs exposed to pulsatile flow. In particular, upregulation of hsa_circ_0007367 stabilized the expressions of endothelial tight junction markers zonula occludens- (ZO-) 1 and occludin, followed by modulating the endothelial nitric oxide synthases (eNOS) activity and inhibiting the NF-κB signaling pathway. CONCLUSION: The modification of pulsatility contributes to microcirculatory perfusion and endothelial integrity during ECMO. The expression of hsa_circ_0007367 plays a pivotal role in this protective mechanism.


Asunto(s)
Ácidos Nucleicos Libres de Células/genética , Células Endoteliales/fisiología , Oxigenación por Membrana Extracorpórea/métodos , Paro Cardíaco/terapia , Animales , Moléculas de Adhesión Celular/metabolismo , Células Cultivadas , Perros , Células Endoteliales/metabolismo , Paro Cardíaco/genética , Paro Cardíaco/patología , Paro Cardíaco/fisiopatología , Inflamación , Pulmón/irrigación sanguínea , Pulmón/patología , Microcirculación , Óxido Nítrico Sintasa de Tipo III/metabolismo , Ocludina/genética , Ocludina/metabolismo , Flujo Pulsátil , Ratas , Proteína de la Zonula Occludens-1/genética , Proteína de la Zonula Occludens-1/metabolismo
2.
Basic Res Cardiol ; 115(3): 31, 2020 04 09.
Artículo en Inglés | MEDLINE | ID: covidwho-46686

RESUMEN

From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease.


Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/fisiopatología , Cardiopatías/tratamiento farmacológico , Cardiopatías/etiología , Enfermedades Pulmonares/tratamiento farmacológico , Enfermedades Pulmonares/etiología , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/fisiopatología , Receptores Notch/antagonistas & inhibidores , Proteína ADAM17/antagonistas & inhibidores , Enzima Convertidora de Angiotensina 2 , Betacoronavirus/efectos de los fármacos , COVID-19 , China , Infecciones por Coronavirus/patología , Infecciones por Coronavirus/virología , Progresión de la Enfermedad , Furina/metabolismo , Paro Cardíaco/etiología , Paro Cardíaco/patología , Cardiopatías/patología , Cardiopatías/fisiopatología , Insuficiencia Cardíaca/etiología , Insuficiencia Cardíaca/patología , Humanos , Interleucina-6/inmunología , Enfermedades Pulmonares/patología , Enfermedades Pulmonares/fisiopatología , Miocarditis/etiología , Miocarditis/patología , Pandemias , Peptidil-Dipeptidasa A/deficiencia , Peptidil-Dipeptidasa A/metabolismo , Neumonía Viral/patología , Neumonía Viral/virología , Receptores Notch/metabolismo , SARS-CoV-2 , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA